Medicine details

ImageAlentin DS 400
NameAlentin DS 400
DosageTablet
Generic NameAlbendazole
Classes Antiinfective Agent
Anthelmintic/Antiparasitic
Diseases Diarrhea
Dizziness
Infectious Disease
Nausea
Stomach Pain
Vomiting
CompanyRenata Limited

Drug Package Details

Strength400 mg
Storage Condition
Origin CountryBangladesh
Commercial Pack25
Price per pack83.75
Cost per pack73.70
Package unit25 tabs strip
Price per unit3.35
Cost per unit2.95
Discount0
Coupon
Remarks

Albendazole

Albendazole is an orally administered broad-spectrum anthelmintic. Albendazole, as a vermicide, produces degenerative changes in the worm's intestinal cells by binding to the colchicine-sensitive region of -tubulin, preventing it from polymerizing or assembling into microtubules.

Hydatid Disease:

  • 60 kg or greater: 400 mg twice daily, with meals in 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles
  • less than 60 kg: 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg), in 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles

Neurocysticercosis:

  • 60 kg or greater: 400 mg twice daily, with meals for 8-30 days.
  • 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg) for 8-30 days.

 

Side effects associated with albendazole include-

  • Gastrointestinal disturbances
  • headache
  • dizziness
  • liver dysfunction
  • rarely reversible alopecia
  • rash
  • fever
  • blood disorders including leucopenia and pancytopenia
  • allergic shock
  • Patients with neurocysticercosis should be treated with steroid and anticonvulsant medications as needed. During the first week of anticysticeral medication, oral or intravenous corticosteroids should be taken to prevent cerebral hypertension events.
  • Patients treated with albendazole for other illnesses may also be found to have pre-existing neurocysticercosis. As a result of an inflammatory reaction triggered by the parasite's demise within the brain, patients may develop neurological symptoms (e.g. seizures, elevated intracranial pressure, and localized signs). Symptoms may appear soon after treatment; steroid and anticonvulsant medication should be started as away.
  • Rare fatalities associated with the use of albendazole have been reported due to granulocytopenia or pancytopenia. Albendazole has been shown to cause bone marrow suppression, aplastic anemia, and agranulocytosis in patients with and without underlying hepatic dysfunction.

Contraindication

Contraindicated in patients with known hypersensitivity to the benzimidazole class of compounds or any components of the medications.

There's no known contraindications of albendazole in terms of food and drinks.

Albendazole should only be administered in pregnant women if no other treatment options are available. Following the discontinuation of albendazole therapy, patients should not become pregnant for at least one month. Albendazole should be stopped immediately if a patient falls pregnant while taking it.